Survival rates of systemic interventions for psoriasis in the Western Japan Psoriasis Registry: A multicenter retrospective study.
Japan
bio-naive
biologics
drug survival
obesity
psoriasis
psoriatic arthritis
systemic intervention
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
revised:
27
12
2022
received:
27
01
2022
accepted:
15
01
2023
medline:
5
6
2023
pubmed:
15
2
2023
entrez:
14
2
2023
Statut:
ppublish
Résumé
Psoriasis affects approximately 0.3% of the Japanese population. Recently, various effective systemic drugs have become available, and the continuation of a given treatment has become critical because of the chronic nature of psoriasis. Factors affecting drug survival (the time until treatment discontinuation) in psoriasis treatment include efficacy, safety, ease of use, and patient preference. In the present study, the authors retrospectively surveyed a multifacility patient registry to determine the real-world evidence of the survival rate of systemic interventions for psoriasis treatment. Patients with psoriasis who visited 20 facilities in the Western Japan area between January 2019 and May 2020 and gave written consent were registered as study participants, and their medical history of systemic interventions for psoriasis (starting from 2010) was retrospectively collected and analyzed. The drugs investigated were adalimumab, infliximab, ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, cyclosporine, and apremilast. When drugs were discontinued, the reasons were also recorded. A total of 1003 patients with psoriasis including 268 with psoriatic arthritis (PsA) were enrolled. In biologics, more recently released drugs such as interleukin 17 inhibitors showed a numerically higher survival rate in the overall (post-2010) analysis. However, in the subset of patients who began treatment after 2017, the difference in the survival rate among the drugs was smaller. The reasons for discontinuing drugs varied, but a loss of efficacy against dermatological or joint symptoms were relatively frequently seen with some biologics and cyclosporine. The stratification of drug survival rates based on patient characteristics such as bio-naive or experienced, normal weight or obese, and with or without PsA, revealed that bio-experienced, obese, and PsA groups had poorer survival rates for most drugs. No notable safety issues were identified in this study. Overall, the present study revealed that the biologics show differences in their tendency to develop a loss of efficacy, and the factors that negatively impact the survival rate of biologics include the previous use of biologics, obesity, and PsA.
Identifiants
pubmed: 36786158
doi: 10.1111/1346-8138.16737
doi:
Substances chimiques
Biological Products
0
Cyclosporine
83HN0GTJ6D
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
753-765Subventions
Organisme : AbbVie
Organisme : Amgen
Organisme : Eisai
Organisme : KyowaKirin
Organisme : Maruho
Organisme : Sunpharma
Organisme : Taiho Yakuhin Kogyo
Informations de copyright
© 2023 Japanese Dermatological Association.
Références
Kubota K, Kamijima Y, Sato T, Ooba N, Koide D, Iizuka H, et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open. 2015;5:e006450.
Kamiya K, Oiso N, Kawada A, Ohtsuki M. Epidemiological survey of the psoriasis patients in the Japanese Society for Psoriasis Research from 2013 to 2018. J Dermatol. 2021;48:864-75.
Lin PT, Wang SH, Chi CC. Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence. Sci Rep. 2018;8:16068.
Tsuruta N, Narisawa Y, Imafuku S, Ito K, Yamaguchi K, Miyagi T, et al. Cross-sectional multicenter observational study of psoriatic arthritis in Japanese patients: relationship between skin and joint symptoms and results of treatment with tumor necrosis factor-alpha inhibitors. J Dermatol. 2019;46:193-8.
Kaneko S, Tsuruta N, Yamaguchi K, Miyagi T, Takahashi K, Higashi Y, et al. Mycobacterium tuberculosis infection in psoriatic patients treated with biologics: real-world data from 18 Japanese facilities. J Dermatol. 2020;47:128-32.
Bayaraa B, Imafuku S. Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka University psoriasis registry. J Dermatol. 2019;46:389-98.
Nestle FO, di Meglio P, Qin JZ, Nickoloff BJ. Skin immune sentinels in health and disease. Nat Rev Immunol. 2009;9:679-91.
Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323:1945-60.
Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83:1583-90.
Rosmarin DM, Lebwohl M, Elewski BE, Gottlieb AB. Cyclosporine and psoriasis: 2008 National Psoriasis Foundation consensus conference. J Am Acad Dermatol. 2010;62:838-53.
Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol. 2007;25:535-46.
Ogawa E, Okuyama R, Seki T, Kobayashi A, Oiso N, Muto M, et al. Epidemiological survey of patients with psoriasis in Matsumoto city, Nagano prefecture, Japan. J Dermatol. 2018;45:314-7.
Burden AD, Warren RB, Kleyn CE, McElhone K, Smith CH, Reynolds NJ, et al. The British Association of Dermatologists' biologic interventions register (BADBIR): design, methodology and objectives. Br J Dermatol. 2012;166:545-54.
Warren RB, Smith CH, Yiu ZZN, Ashcroft DM, Barker JNWN, Burden AD, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists biologic interventions register (BADBIR). J Invest Dermatol. 2015;135:2632-40.
Menter A, Papp KA, Gooderham M, Pariser DM, Augustin M, Kerdel FA, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016;30:1148-58.
Egeberg A, Ottosen MB, Gniadecki R, Broesby-Olsen S, Dam TN, Bryld LE, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178:509-19.
Umezawa Y, Nobeyama Y, Hayashi M, Fukuchi O, Ito T, Saeki H, et al. Drug survival rates in patients with psoriasis after treatment with biologics. J Dermatol. 2013;40:1008-13.
Kishimoto M, Komine M, Kamiya K, Sugai J, Mieno M, Ohtsuki M. Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan. J Dermatol. 2020;47:33-40.
Ohata C, Ohyama B, Katayama E, Nakama T. Real-world efficacy and safety of interleukin-17 inhibitors for psoriasis: a single-center experience. J Dermatol. 2020;47:405-8.
Kara Polat A, Oguz Topal I, Aslan Kayıran M, Koku Aksu AE, Aytekin S, Topaloglu Demir F, et al. Drug survival and safety profile of acitretin monotherapy in patients with psoriasis: a multicenter retrospective study. Dermatol Ther. 2021;34:e14834.
Puig L, Carrascosa JM, Daudén E, Sulleiro S, Guisado C. Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study. J Dermatolog Treat. 2020;31:344-51.
Chularojanamontri L, Silpa-Archa N, Wongpraparut C, Limphoka P. Long-term safety and drug survival of acitretin in psoriasis: a retrospective observational study. Int J Dermatol. 2019;58:593-9.
Kapniari E, Dalamaga M, Papadavid E. Comorbidities burden and previous exposure to biological agents may predict drug survival of apremilast for psoriasis in a real-world setting. Dermatol Ther. 2020;33:e14168.
Kishimoto M, Komine M, Kamiya K, Sugai J, Ohtsuki M. Drug survival of apremilast in a real-world setting. J Dermatol. 2019;46:615-7.
Ohata C, Ohyama B, Kuwahara F, Katayama E, Nakama T. Real-world data on the efficacy and safety of apremilast in Japanese patients with plaque psoriasis. J Dermatolog Treat. 2019;30:383-6.
Saruwatari H. Real-world experiences of apremilast in clinics for Japanese patients with psoriasis. J Dermatol. 2019;46:1166-9.
Shalom G, Zisman D, Harman-Boehm I, Biterman H, Greenberg-Dotan S, Polishchuk I, et al. Factors associated with drug survival of methotrexate and acitretin in patients with psoriasis. Acta Derm Venereol. 2015;95:973-7.
Ergun T, Seckin Gencosmanoglu D, Alpsoy E, Bulbul-Baskan E, Saricam MH, Salman A, et al. Efficacy, safety and drug survival of conventional agents in pediatric psoriasis: a multicenter, cohort study. J Dermatol. 2017;44:630-4.
Lockshin B, Cronin A, Harrison RW, McLean RR, Anatale-Tardiff L, Burge R, et al. Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: the Corrona psoriasis registry. Dermatol Ther. 2021;34:e14808.
Graier T, Salmhofer W, Jonak C, Weger W, Kölli C, Gruber B, et al. Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis. Br J Dermatol. 2021;184:1094-105.
Sara A, Ignacio V, Fernández S, Martín JL, Charca L, Pino M, et al. Multicenter study of Secukinumab survival and safety in Spondyloarthritis and psoriatic arthritis: Secukinumab in Cantabria and ASTURias study. Front Med. 2021;8:679009. https://doi.org/10.3389/fmed.2021
Nawaf AM, Tarek N. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial. Expert Opin Biol Ther. 2014;14:749-56.
Matthias A, Kristian R, Yamauchi P, Pinter A, Bagel J, Dahale S, et al. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial. Br J Dermatol. 2022;186:942-54.
Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, et al. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists biologics and Immunomodulators register (BADBIR). Br J Dermatol. 2020;183:294-302.
Alexander E, Nana AL, Lene D, Lørup EH, Nielsen ML, Nymand L, et al. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - a nationwide cohort study from the DANBIO and DERMBIO registries. Semin Arthritis Rheum. 2022;53:151979.